CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

All Catalyst Types

Phase 3 Clinical Trials

As of Nov 17, 2026, CatalystAlert tracks 460 upcoming phase 3 clinical trials: 9 with the exact day known, the rest estimated by month from sources such as ClinicalTrials.gov and company filings. Next up: DSGN, GSK, KRTX.

Pivotal, large-scale trials that confirm a drug’s efficacy and safety. Positive Phase 3 data is usually the gateway to FDA submission.

These dates are public. The filterable calendar, alerts, exports and AI research are in the app — free account: the next 7 days and 3 companies you track. Plans →

460 UpcomingView Full Calendar

November 202612

Nov '26
DSGNPhase 3

ALECENSA - alectinib hydrochloride capsule Phase 3 Est. Readout (Drugs-SNPs)

ALECENSA - alectinib hydrochloride capsule
Nov 2026~
CT.gov
00%
Nov '26
GSKPhase 3

dTpa Phase 3 Est. Readout

dTpa
Nov 2026~
CT.gov
00%
Nov '26
KRTXPhase 3

KarXT Phase 3 Est. Readout

KarXT
Nov 2026~
CT.gov
00%
Nov '26
MKKGYPhase 3

Avelumab Phase 3 Est. Readout

Avelumab
Nov 2026~
CT.gov
00%
Nov '26
SNYPhase 3

rilzabrutinib Phase 3 Est. Readout

Rilzabrutinib
Nov 2026~
CT.gov
00%
Nov '26
SNYPhase 3

Measles, combinations with mumps and rubella, live attenuated Phase 3 Est. Readout

Measles, combinations with mumps and rubella, live attenuated
Nov 2026~
CT.gov
00%
Q4 '26
PFEPhase 3

Rimegepant Phase 3 Est. Readout

Rimegepant
Q4 2026~Q
CT.gov
00%
Nov '26
PHARPhase 3

Leniolisib Phase 3 Est. Readout

Leniolisib
Nov 2026~
CT.gov
00%
Nov '26
SKBBYPhase 3

A166 Phase 3 Est. Readout

A166
Nov 2026~
CT.gov
00%
Q4 '26
IRLAPhase 3

Dexamethasone sodium phosphate Phase 3 Est. Readout

Dexamethasone sodium phosphate
Q4 2026~Q
CT.gov
00%
Nov '26
TXMDPhase 3

GS1191-0445 injection Phase 3 Est. Readout

GS1191-0445 injection
Nov 2026~
CT.gov
00%
Nov '26
RHHBYPhase 3

Atezolizumab Phase 3 Est. Readout

Atezolizumab
Nov 2026~
CT.gov
00%

December 202668

Dec '26
BIIBPhase 3

Felzartamab Phase 3 Est. Readout (TRANSCEND)

Felzartamab
Dec 2026~
CT.gov
00%
Dec '26
SNYPhase 3

PCV21 Phase 3 Est. Readout

PCV21
Dec 2026~
CT.gov
00%
Dec '26
PFEPhase 3

Ritlecitinib higher dose Phase 3 Est. Readout (B7981027)

Ritlecitinib higher dose
Dec 2026~
CT.gov
00%
Dec '26
PFEPhase 3

VLA15 Phase 3 Est. Readout

VLA15
Dec 2026~
CT.gov
00%
Dec '26
AZNPhase 3

eculizumab Phase 3 Est. Readout (ECU-NMO-304)

Eculizumab
Dec 2026~
CT.gov
00%
Dec '26
AMGNPhase 3

ABP 234 Phase 3 Est. Readout (Eucalyptus)

ABP 234
Dec 2026~
CT.gov
00%
Dec '26
4519.TPhase 3

Ifosfamide or dacarbazine Phase 3 Est. Readout (CIRSARC)

Ifosfamide or dacarbazine
Dec 2026~
CT.gov
00%
Dec '26
PRAXPhase 3

PRAX-562 Phase 3 Est. Readout (EMERALD)

PRAX-562
Dec 2026~
CT.gov
00%
Dec '26
RGNXPhase 3

Ranibizumab (LUCENTIS®) Phase 3 Est. Readout (ATMOSPHERE)

Ranibizumab (LUCENTIS®)
Dec 2026~
CT.gov
00%
Dec '26
GOSSPhase 3

Seralutinib Phase 3 Est. Readout

Seralutinib
Dec 2026~
CT.gov
00%
Dec '26
KRYSPhase 3

KB803 Phase 3 Est. Readout (IOLITE)

KB803
Dec 2026~
CT.gov
00%
Dec '26
GNLXPhase 3

olvimulogene nanivacirepvec Phase 3 Est. Readout

olvimulogene nanivacirepvec
Dec 2026~
CT.gov
00%
Dec '26
IONSPhase 3

Donidalorsen Phase 3 Est. Readout

Donidalorsen
Dec 2026~
CT.gov
00%
Dec '26
AVIRPhase 3

Bemnifosbuvir-Ruzasvir Phase 3 Est. Readout

Bemnifosbuvir-Ruzasvir
Dec 2026~
CT.gov
00%
Dec '26
KPTIPhase 3

Selinexor (combination therapy) Phase 3 Est. Readout

Selinexor (combination therapy)
Dec 2026~
CT.gov
00%
Dec '26
WXIPhase 3

Mesenchymal Stem Cells Phase 3 Est. Readout

Mesenchymal Stem Cells
Dec 2026~
CT.gov
00%
Dec '26
MDGLPhase 3

Resmetirom Phase 3 Est. Readout

Resmetirom
Dec 2026~
CT.gov
00%
Dec '26
BHVNPhase 3

BHV-7000 Phase 3 Est. Readout (RISE 2)

BHV-7000
Dec 2026~
CT.gov
00%
Dec '26
IPSEYPhase 3

Corabotase Phase 3 Est. Readout (LAURITE 2)

Corabotase
Dec 2026~
CT.gov
00%
Dec '26
JHPCYPhase 3

Lutetium (177Lu) Oxodotreotide Injection;long-acting Octreotide Phase 3 Est. Readout

Lutetium (177Lu) Oxodotreotide Injection;long-acting Octreotide
Dec 2026~
CT.gov
00%
Dec '26
OCSPhase 3

licaminlimab Phase 3 Est. Readout (PREDICT-1)

licaminlimab
Dec 2026~
CT.gov
00%
Dec '26
AZNPhase 3

Durvalumab Phase 3 Est. Readout (CompARE)

Durvalumab
Dec 2026~
CT.gov
00%
Dec '26
RHHBYPhase 3

Atezolizumab Phase 3 Est. Readout (APTneo)

Atezolizumab
Dec 2026~
CT.gov
00%
Dec '26
MDWDPhase 3

EscharEx (EX-03) Phase 3 Est. Readout (VALUE)

EscharEx (EX-03)
Dec 2026~
CT.gov
00%
Dec '26
EXELPhase 3

XL092 Phase 3 Est. Readout (STELLAR-304)

XL092
Dec 2026~
CT.gov
00%
Dec '26
ABBVPhase 3

Lutikizumab Phase 3 Est. Readout (Intrepid)

Lutikizumab
Dec 2026~
CT.gov
00%
Dec '26
AXSMPhase 3

Solriamfetol Phase 3 Est. Readout

Solriamfetol
Dec 2026~
CT.gov
00%
Dec '26
ALDXPhase 3

ICM ADX-2191 injection Phase 3 Est. Readout

ICM ADX-2191 injection
Dec 2026~
CT.gov
00%
Dec '26
JNJPhase 3

Nipocalimab Phase 3 Est. Readout

Nipocalimab
Dec 2026~
CT.gov
00%
Dec '26
BCRXPhase 3

navenibart Phase 3 Est. Readout

navenibart
Dec 2026~
CT.gov
00%
Dec '26
IPN.PAPhase 3

Corabotase Phase 3 Est. Readout (LAURITE 1)

Corabotase
Dec 2026~
CT.gov
00%
Dec '26
PCRXPhase 3

ZILRETTA Phase 3 Est. Readout

ZILRETTA
Dec 2026~
CT.gov
00%
Dec '26
SKBBYPhase 3

SKB264 Phase 3 Est. Readout

SKB264
Dec 2026~
CT.gov
00%
Dec '26
DMACPhase 3

Recombinant human tissue kallikrein Phase 3 Est. Readout (ReMEDy2)

Recombinant human tissue kallikrein
Dec 2026~
CT.gov
00%
Dec '26
4519.TPhase 3

Satralizumab Phase 3 Est. Readout (Cielo)

Satralizumab
Dec 2026~
CT.gov
00%
Dec '26
RHHBYPhase 3

Satralizumab Phase 3 Est. Readout

satralizumab
Dec 2026~
CT.gov
00%
Dec '26
IPSEYPhase 3

Elafibranor Phase 3 Est. Readout (ELONSEN)

Elafibranor
Dec 2026~
CT.gov
00%
Q4 '26
UCBJYPhase 3

Bimekizumab Phase 3 Est. Readout

Bimekizumab
Q4 2026~Q
CT.gov
00%
Dec '26
AZNPhase 3

Benralizumab Phase 3 Est. Readout (DOMINICA)

Benralizumab
Dec 2026~
CT.gov
00%
Dec '26
GSKPhase 3

Investigational varicella vaccine_Lot 1 Phase 3 Est. Readout

Investigational varicella vaccine_Lot 1
Dec 2026~
CT.gov
00%
Dec '26
INCYPhase 3

Povorcitinib Phase 3 Est. Readout (STOP-HS LTE)

Povorcitinib
Dec 2026~
CT.gov
00%
Dec '26
IQVPhase 3

Oregovomab Phase 3 Est. Readout (FLORA-5)

Oregovomab
Dec 2026~
CT.gov
00%
Dec '26
ARVNPhase 3

Vepdegestrant (ARV-471/PF-07850327) Phase 3 Est. Readout (VERITAC-3)

Vepdegestrant (ARV-471/PF-07850327)
Dec 2026~
CT.gov
00%
Dec '26
JHPCYPhase 3

Hepatectomy Combined With Camrelizumab and Apatinib Phase 3 Est. Readout

Hepatectomy Combined With Camrelizumab and Apatinib
Dec 2026~
CT.gov
00%
Dec '26
RNACPhase 3

Decartes-08 Phase 3 Est. Readout

Decartes-08
Dec 2026~
CT.gov
00%
Dec '26
QNRXPhase 3

QRX003, Lotion Phase 3 Est. Readout

QRX003, Lotion
Dec 2026~
CT.gov
00%
Dec '26
PFEPhase 3

ARV-471 (PF-07850327) Phase 3 Est. Readout

ARV-471 (PF-07850327)
Dec 2026~
CT.gov
00%
Dec '26
IVBXFPhase 3

IBI343 Phase 3 Est. Readout (G-HOPE-001)

IBI343
Dec 2026~
CT.gov
00%
Dec '26
BIIBPhase 3

Lecanemab SC Phase 3 Est. Readout (Clarity AD)

Lecanemab SC
Dec 2026~
CT.gov
00%
Dec '26
ONCPhase 3

Zanubrutinib Phase 3 Est. Readout

Zanubrutinib
Dec 2026~
CT.gov
00%
Dec '26
PCYCPhase 3

Ibrutinib Phase 3 Est. Readout (CAN3001)

Ibrutinib
Dec 2026~
CT.gov
00%
Dec '26
GALD.SWPhase 3

Trifarotene Phase 3 Est. Readout (AKLIEF)

Trifarotene
Dec 2026~
CT.gov
00%
Dec '26
MRKPhase 3

9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Phase 3 Est. Readout

9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)
Dec 2026~
CT.gov
00%
Dec '26
PFEPhase 3

Avelumab Phase 3 Est. Readout

Avelumab
Dec 2026~
CT.gov
00%
2mo
KODPhase 3

Phase 3 — KSI-101

Dec 31
Source
00%
Dec '26
AAPGPhase 3

lisaftoclax +BTK inhibitor Phase 3 Est. Readout

lisaftoclax +BTK inhibitor
Dec 2026~
CT.gov
00%
2mo
IMUXPhase 3

Phase 3

Dec 31
Source
00%
Q4 '26
BMRNPhase 3

migalastat HCl Phase 3 Est. Readout

migalastat HCl
Q4 2026~Q
CT.gov
00%
Dec '26
INSMPhase 3

Treprostinil Palmitil Phase 3 Est. Readout

Treprostinil Palmitil
Dec 2026~
CT.gov
00%
Dec '26
BMYPhase 3

Phase 3 Results - Cobenfy

Dec 2026~
Source
00%
Dec '26
ALPMYPhase 3

Enzalutamide Phase 3 Est. Readout (ENZAMET)

Enzalutamide
Dec 2026~
CT.gov
00%
Dec '26
AZNPhase 3

Androgen blockade + radiation therapy Phase 3 Est. Readout (PCS IV)

Androgen blockade + radiation therapy
Dec 2026~
CT.gov
00%
Dec '26
IVBXFPhase 3

IBI362 Phase 3 Est. Readout

IBI362
Dec 2026~
CT.gov
00%
Dec '26
SKBBYPhase 3

SKB264 Phase 3 Est. Readout

SKB264
Dec 2026~
CT.gov
00%
Dec '26
TEVAPhase 3

TEV-56248 Phase 3 Est. Readout

TEV-56248
Dec 2026~
CT.gov
00%
Dec '26
JHPCYPhase 3

Fuzuloparib, Abiraterone acetate and Prednisone Phase 3 Est. Readout

Fuzuloparib, Abiraterone acetate and Prednisone
Dec 2026~
CT.gov
00%
Dec '26
HNPHYPhase 3

Almonertinib Phase 3 Est. Readout (APPROACH)

Almonertinib
Dec 2026~
CT.gov
00%
2mo
VTRSPhase 3

Phase 3 — VR-205

Dec 31
Source
00%

January 202720

Jan '27
RGNXPhase 3

Phase 3

Jan 2027~
Source
00%
Jan '27
RNXTPhase 3

Phase 3

Jan 2027~
Source
00%
Jan '27
AZNPhase 3

AZD0780 Phase 3 Est. Readout (AZURE-HeFH)

AZD0780
Jan 2027~
CT.gov
00%
Jan '27
MLTXPhase 3

Sonelokimab Phase 3 Est. Readout (IZAR-2)

Sonelokimab
Jan 2027~
CT.gov
00%
Jan '27
PHO.OLPhase 3

Cysview Phase 3 Est. Readout

Cysview
Jan 2027~
CT.gov
00%
Jan '27
SNYPhase 3

PCV21 Phase 3 Est. Readout

PCV21
Jan 2027~
CT.gov
00%
Jan '27
OCULPhase 3

OTX-TKI Phase 3 Est. Readout

OTX-TKI
Jan 2027~
CT.gov
00%
Jan '27
AZNPhase 3

AZD0780 Phase 3 Est. Readout (AZURE-LDL)

AZD0780
Jan 2027~
CT.gov
00%
Jan '27
DSKYFPhase 3

Dato-DXd Phase 3 Est. Readout (TROPION-Lung15)

Dato-DXd
Jan 2027~
CT.gov
00%
Jan '27
GILDPhase 3

Sacituzumab Govitecan Phase 3 Est. Readout

Sacituzumab Govitecan
Jan 2027~
CT.gov
00%
Jan '27
SNYPhase 3

efanesoctocog alfa (BIVV001) Phase 3 Est. Readout (XTEND-ed)

efanesoctocog alfa (BIVV001)
Jan 2027~
CT.gov
00%
Jan '27
PRAXPhase 3

vormatrogine Phase 3 Est. Readout (POWER2)

vormatrogine
Jan 2027~
CT.gov
00%
Jan '27
REGNPhase 3

Cemiplimab Phase 3 Est. Readout

cemiplimab
Jan 2027~
CT.gov
00%
Jan '27
XENEPhase 3

Azetukalner Phase 3 Est. Readout (X-NOVA-OLE)

Azetukalner
Jan 2027~
CT.gov
00%
Jan '27
MRKPhase 3

9vHPV Vaccine Phase 3 Est. Readout

9vHPV vaccine
Jan 2027~
CT.gov
00%
Jan '27
TLXPhase 3

68Ga-PSMA-11 Phase 3 Est. Readout (BiPASS)

68Ga-PSMA-11
Jan 2027~
CT.gov
00%
Jan '27
ABBVPhase 3

Livmoniplimab Phase 3 Est. Readout (LIVIGNO-2)

Livmoniplimab
Jan 2027~
CT.gov
00%
Jan '27
RAREPhase 3

setrusumab Phase 3 Est. Readout

setrusumab
Jan 2027~
CT.gov
00%
Jan '27
IDYAPhase 3

IDE196 Phase 3 Est. Readout

IDE196
Jan 2027~
CT.gov
00%
Jan '27
SVAPhase 3

experimental vaccine Phase 3 Est. Readout

Experimental vaccine
Jan 2027~
CT.gov
00%
Get Phase 3 Clinical Trials Alerts

About Phase 3 Clinical Trials

Phase 3 clinical trials are large, randomized, often placebo- or active-controlled studies that test a drug’s efficacy and safety in hundreds to thousands of patients. They are the pivotal trials regulators rely on to decide whether a therapy works well enough to approve.

A Phase 3 program typically reads out on pre-specified primary and secondary endpoints. Topline results — the first public disclosure of whether the trial hit its main endpoint — are the market-moving moment, well before the full data appears at a medical congress or in a peer-reviewed journal.

Why Phase 3 Trials matter to investors

Phase 3 readouts are high-variance catalysts: a hit clears the path to an NDA/BLA and often a partnership or run-up, while a miss can erase most of a clinical-stage company’s value in a single session. Historically around 58% of drugs that reach Phase 3 ultimately win approval — better than a coin flip, but far from certain — so the readout is where much of a pipeline’s risk is priced.

Frequently asked questions

What is a Phase 3 clinical trial?

A Phase 3 trial is a large, pivotal study — often hundreds to thousands of patients — that confirms a drug’s efficacy and safety and forms the basis of an FDA or EMA submission.

What does a Phase 3 “topline” readout mean?

Topline results are the first public disclosure of whether the trial met its primary endpoint. They arrive before the full dataset and are the main price-moving event.

How often do Phase 3 trials succeed?

Success is far from guaranteed — historically around 58% of drugs that reach Phase 3 go on to approval, which is why a positive readout can re-rate a stock and a failure can be severe.